News
-
-
-
-
PRESS RELEASE
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies updates on BLA submission for VIASKIN Peanut Patch in children aged 4-7 years, optimizing the review process with FDA for a complete and efficient review -
-
-
PRESS RELEASE
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
DBV Technologies has been included in the Euronext Tech Leaders index, spotlighting high-growth European companies in technology and adjacent sectors. The recognition reflects the company's progress in developing innovative treatment options -
-
-
PRESS RELEASE
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies to participate in 1-on-1 investor meetings at Goldman Sachs Annual Global Healthcare Conference. CEO unavailable for fireside chat. Company focused on developing food allergy treatments with VIASKIN patch technology